Anya Mezina1, Neil Philips1, Zoe Bogus1,2, Noam Erez1, Rui Xiao3, Ruoming Fan1, Kim M Olthoff4, K Rajender Reddy1, N Jewel Samadder5, Sarah M Nielsen6, Kathryn E Hatchell6, Edward D Esplin6, Anil K Rustgi7, Bryson W Katona1, Maarouf A Hoteit1, Katherine L Nathanson1,8, Kirk J Wangensteen1,2,8. 1. Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 2. Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 3. Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 4. Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 5. Mayo Clinic, Phoenix, AZ. 6. Invitae Corp, San Francisco, CA. 7. Division of Digestive and Liver Diseases, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY. 8. Abramson Cancer Center, University of Perelman School of Medicine, Philadelphia, PA.
Abstract
Hepatocellular carcinoma (HCC) has well-defined environmental risk factors. In addition, epidemiologic studies have suggested hereditary risk factors. The goals of this study were to determine the rate of pathogenic and likely pathogenic (P/LP) germline variants in cancer predisposition genes in patients with HCC, possible enrichment of P/LP variants in particular genes, and potential impact on clinical management. MATERIALS AND METHODS: A prospective study at a tertiary medical center enrolled 217 patients with a personal history of HCC. Multigene panel testing was performed for 134 cancer predisposition genes in all patients. The rate of P/LP variants was compared with population rates. A separate retrospective cohort included 219 patients with HCC who underwent testing at a commercial laboratory. RESULTS: In the prospective cohort, P/LP germline variants were identified in 25 of 217 patients with HCC (11.5%). Four patients (1.8%) had P/LP variants in the highly penetrant cancer genes BRCA2 (n = 2), MSH6 (n = 1), and PMS2 (n = 1). In addition, multiple patients had P/LP variants in FANCA (n = 5) and BRIP1 (n = 4), which were significantly enriched in HCC compared with the general population. Detection of P/LP variants led to changes in clinical management in regard to therapy selection, screening recommendations, and cascade testing of relatives. In a separate retrospective analysis of 219 patients with HCC, 30 (13.7%) were positive for P/LP variants including 13 (5.9%) with highly penetrant genes APC (n = 2), BRCA1 (n = 1), BRCA2 (n = 6), MSH2 (n = 2), or TP53 (n = 2). CONCLUSION: P/LP germline variants in cancer predisposition genes were detected in 11%-14% of patients with HCC. Inherited genetics should not be overlooked in HCC as there are important implications for precision treatment, future risk of cancers, and familial cancer risk.
Hepatocellular carcinoma (HCC) has well-defined environmental risk factors. In addition, epidemiologic studies have suggested hereditary risk factors. The goals of this study were to determine the rate of pathogenic and likely pathogenic (P/LP) germline variants in cancer predisposition genes in patients with HCC, possible enrichment of P/LP variants in particular genes, and potential impact on clinical management. MATERIALS AND METHODS: A prospective study at a tertiary medical center enrolled 217 patients with a personal history of HCC. Multigene panel testing was performed for 134 cancer predisposition genes in all patients. The rate of P/LP variants was compared with population rates. A separate retrospective cohort included 219 patients with HCC who underwent testing at a commercial laboratory. RESULTS: In the prospective cohort, P/LP germline variants were identified in 25 of 217 patients with HCC (11.5%). Four patients (1.8%) had P/LP variants in the highly penetrant cancer genes BRCA2 (n = 2), MSH6 (n = 1), and PMS2 (n = 1). In addition, multiple patients had P/LP variants in FANCA (n = 5) and BRIP1 (n = 4), which were significantly enriched in HCC compared with the general population. Detection of P/LP variants led to changes in clinical management in regard to therapy selection, screening recommendations, and cascade testing of relatives. In a separate retrospective analysis of 219 patients with HCC, 30 (13.7%) were positive for P/LP variants including 13 (5.9%) with highly penetrant genes APC (n = 2), BRCA1 (n = 1), BRCA2 (n = 6), MSH2 (n = 2), or TP53 (n = 2). CONCLUSION: P/LP germline variants in cancer predisposition genes were detected in 11%-14% of patients with HCC. Inherited genetics should not be overlooked in HCC as there are important implications for precision treatment, future risk of cancers, and familial cancer risk.
Authors: Mark A Jenkins; Marina E Croitoru; Neerav Monga; Sean P Cleary; Michelle Cotterchio; John L Hopper; Steven Gallinger Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-02 Impact factor: 4.254
Authors: Kuan-Lin Huang; R Jay Mashl; Yige Wu; Deborah I Ritter; Jiayin Wang; Clara Oh; Marta Paczkowska; Sheila Reynolds; Matthew A Wyczalkowski; Ninad Oak; Adam D Scott; Michal Krassowski; Andrew D Cherniack; Kathleen E Houlahan; Reyka Jayasinghe; Liang-Bo Wang; Daniel Cui Zhou; Di Liu; Song Cao; Young Won Kim; Amanda Koire; Joshua F McMichael; Vishwanathan Hucthagowder; Tae-Beom Kim; Abigail Hahn; Chen Wang; Michael D McLellan; Fahd Al-Mulla; Kimberly J Johnson; Olivier Lichtarge; Paul C Boutros; Benjamin Raphael; Alexander J Lazar; Wei Zhang; Michael C Wendl; Ramaswamy Govindan; Sanjay Jain; David Wheeler; Shashikant Kulkarni; John F Dipersio; Jüri Reimand; Funda Meric-Bernstam; Ken Chen; Ilya Shmulevich; Sharon E Plon; Feng Chen; Li Ding Journal: Cell Date: 2018-04-05 Impact factor: 41.582
Authors: Ronja Adam; Isabel Spier; Bixiao Zhao; Michael Kloth; Jonathan Marquez; Inga Hinrichsen; Jutta Kirfel; Aylar Tafazzoli; Sukanya Horpaopan; Siegfried Uhlhaas; Dietlinde Stienen; Nicolaus Friedrichs; Janine Altmüller; Andreas Laner; Stefanie Holzapfel; Sophia Peters; Katrin Kayser; Holger Thiele; Elke Holinski-Feder; Giancarlo Marra; Glen Kristiansen; Markus M Nöthen; Reinhard Büttner; Gabriela Möslein; Regina C Betz; Angela Brieger; Richard P Lifton; Stefan Aretz Journal: Am J Hum Genet Date: 2016-07-28 Impact factor: 11.025
Authors: Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach Journal: Hepatology Date: 2018-08 Impact factor: 17.425
Authors: C Cybulski; B Górski; T Huzarski; B Masojć; M Mierzejewski; T Debniak; U Teodorczyk; T Byrski; J Gronwald; J Matyjasik; E Zlowocka; M Lenner; E Grabowska; K Nej; J Castaneda; K Medrek; A Szymańska; J Szymańska; G Kurzawski; J Suchy; O Oszurek; A Witek; S A Narod; J Lubiński Journal: Am J Hum Genet Date: 2004-10-18 Impact factor: 11.025
Authors: Manal M Hassan; Margret R Spitz; Melanie B Thomas; Steven A Curley; Yehuda Z Patt; Jean-Nicolas Vauthey; Katrina Y Glover; Ahmed Kaseb; Richard D Lozano; Adel S El-Deeb; Nga T Nguyen; Steven H Wei; Wenyaw Chan; James L Abbruzzese; Donghui Li Journal: J Hepatol Date: 2008-10-16 Impact factor: 25.083
Authors: Piper Nicolosi; Elisa Ledet; Shan Yang; Scott Michalski; Brandy Freschi; Erin O'Leary; Edward D Esplin; Robert L Nussbaum; Oliver Sartor Journal: JAMA Oncol Date: 2019-04-01 Impact factor: 31.777
Authors: N Jewel Samadder; Douglas Riegert-Johnson; Lisa Boardman; Deborah Rhodes; Myra Wick; Scott Okuno; Katie L Kunze; Michael Golafshar; Pedro L S Uson; Luke Mountjoy; Natalie Ertz-Archambault; Neej Patel; Eduardo A Rodriguez; Blanca Lizaola-Mayo; Michael Lehrer; Cameron S Thorpe; Nathan Y Yu; Edward D Esplin; Robert L Nussbaum; Richard R Sharp; Cindy Azevedo; Margaret Klint; Megan Hager; Sarah Macklin-Mantia; Alan H Bryce; Tanios S Bekaii-Saab; Aleksandar Sekulic; A Keith Stewart Journal: JAMA Oncol Date: 2021-02-01 Impact factor: 31.777
Authors: Edward D Esplin; Sarah M Nielsen; Sara L Bristow; Judy E Garber; Heather Hampel; Huma Q Rana; N Jewel Samadder; Neal D Shore; Robert L Nussbaum Journal: JCO Precis Oncol Date: 2022-09